[谢切诺夫大学心脏肿瘤中心的 4 年经验:单中心流行病学研究]。

IF 0.5 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Yu Yu Kirichenko, I S Ilgisonis, A D Chernichkina, A V Palienko, O I Buduscheva, N N Pakhtusov, N V Khabarova, Yu N Belenkov
{"title":"[谢切诺夫大学心脏肿瘤中心的 4 年经验:单中心流行病学研究]。","authors":"Yu Yu Kirichenko, I S Ilgisonis, A D Chernichkina, A V Palienko, O I Buduscheva, N N Pakhtusov, N V Khabarova, Yu N Belenkov","doi":"10.18087/cardio.2024.10.n2768","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To present the four-year experience and the accomplishments of the Scientific and Practical Cardio-Oncology Center of the Sechenov University.</p><p><strong>Material and methods: </strong>The records of patients referred for cardio-oncology consultation from January 2020 through March 2024 were retrospectively analyzed. The patients' cardiovascular (CV) status was assessed at baseline and after optimizing the cardiac therapy during the antitumor treatment. The endpoints were the completion of all antitumor therapy courses and the level of overall and CV mortality.</p><p><strong>Results: </strong>Among 233 enrolled patients (66% women), a considerable part belonged to the group of high/very high cardio-oncological risk (n=134, 57%). Various cardiovascular toxicities were observed in 22% of patients. At baseline, these patients significantly more frequently had heart failure and ischemic heart disease as well as previous radiation and chemotherapy. After the optimization of cardiac therapy, 88% of patients successfully completed all scheduled treatments. The overall mortality, including the CV mortality, was 14% (n=7).</p><p><strong>Conclusion: </strong>Creation of cardio-oncological services allows considerably reducing the probability of adverse CV events during the antitumor therapy and successfully completing all scheduled treatments in most patients..</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"64 10","pages":"32-39"},"PeriodicalIF":0.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[4‑Year Experience of the Cardio-Oncology Center of Sechenov University: Single-Center Epidemiological Study].\",\"authors\":\"Yu Yu Kirichenko, I S Ilgisonis, A D Chernichkina, A V Palienko, O I Buduscheva, N N Pakhtusov, N V Khabarova, Yu N Belenkov\",\"doi\":\"10.18087/cardio.2024.10.n2768\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To present the four-year experience and the accomplishments of the Scientific and Practical Cardio-Oncology Center of the Sechenov University.</p><p><strong>Material and methods: </strong>The records of patients referred for cardio-oncology consultation from January 2020 through March 2024 were retrospectively analyzed. The patients' cardiovascular (CV) status was assessed at baseline and after optimizing the cardiac therapy during the antitumor treatment. The endpoints were the completion of all antitumor therapy courses and the level of overall and CV mortality.</p><p><strong>Results: </strong>Among 233 enrolled patients (66% women), a considerable part belonged to the group of high/very high cardio-oncological risk (n=134, 57%). Various cardiovascular toxicities were observed in 22% of patients. At baseline, these patients significantly more frequently had heart failure and ischemic heart disease as well as previous radiation and chemotherapy. After the optimization of cardiac therapy, 88% of patients successfully completed all scheduled treatments. The overall mortality, including the CV mortality, was 14% (n=7).</p><p><strong>Conclusion: </strong>Creation of cardio-oncological services allows considerably reducing the probability of adverse CV events during the antitumor therapy and successfully completing all scheduled treatments in most patients..</p>\",\"PeriodicalId\":54750,\"journal\":{\"name\":\"Kardiologiya\",\"volume\":\"64 10\",\"pages\":\"32-39\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kardiologiya\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18087/cardio.2024.10.n2768\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kardiologiya","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18087/cardio.2024.10.n2768","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:介绍谢切诺夫大学科学实践心脏肿瘤中心四年来的经验和成就:回顾性分析了 2020 年 1 月至 2024 年 3 月期间转诊的肿瘤心脏病患者的病历。对患者的心血管(CV)状况进行了基线评估和抗肿瘤治疗期间优化心脏治疗后的评估。终点是所有抗肿瘤治疗疗程的完成情况以及总死亡率和心血管死亡率:在233名入选患者(66%为女性)中,相当一部分属于心血管肿瘤高危/极高危人群(134人,57%)。22%的患者出现了各种心血管毒性反应。基线时,这些患者中患有心力衰竭和缺血性心脏病以及接受过放疗和化疗的人数明显增多。在优化心脏治疗后,88% 的患者成功完成了所有预定治疗。包括心血管疾病在内的总死亡率为14%(7人):结论:建立心脏肿瘤服务可大大降低抗肿瘤治疗期间发生不良心血管事件的概率,并使大多数患者成功完成所有预定治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[4‑Year Experience of the Cardio-Oncology Center of Sechenov University: Single-Center Epidemiological Study].

Aim: To present the four-year experience and the accomplishments of the Scientific and Practical Cardio-Oncology Center of the Sechenov University.

Material and methods: The records of patients referred for cardio-oncology consultation from January 2020 through March 2024 were retrospectively analyzed. The patients' cardiovascular (CV) status was assessed at baseline and after optimizing the cardiac therapy during the antitumor treatment. The endpoints were the completion of all antitumor therapy courses and the level of overall and CV mortality.

Results: Among 233 enrolled patients (66% women), a considerable part belonged to the group of high/very high cardio-oncological risk (n=134, 57%). Various cardiovascular toxicities were observed in 22% of patients. At baseline, these patients significantly more frequently had heart failure and ischemic heart disease as well as previous radiation and chemotherapy. After the optimization of cardiac therapy, 88% of patients successfully completed all scheduled treatments. The overall mortality, including the CV mortality, was 14% (n=7).

Conclusion: Creation of cardio-oncological services allows considerably reducing the probability of adverse CV events during the antitumor therapy and successfully completing all scheduled treatments in most patients..

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Kardiologiya
Kardiologiya 医学-心血管系统
CiteScore
1.70
自引率
20.00%
发文量
94
审稿时长
3-8 weeks
期刊介绍: “Kardiologiya” (Cardiology) is a monthly scientific, peer-reviewed journal committed to both basic cardiovascular medicine and practical aspects of cardiology. As the leader in its field, “Kardiologiya” provides original coverage of recent progress in cardiovascular medicine. We publish state-of-the-art articles integrating clinical and research activities in the fields of basic cardiovascular science and clinical cardiology, with a focus on emerging issues in cardiovascular disease. Our target audience spans a diversity of health care professionals and medical researchers working in cardiovascular medicine and related fields. The principal language of the Journal is Russian, an additional language – English (title, authors’ information, abstract, keywords). “Kardiologiya” is a peer-reviewed scientific journal. All articles are reviewed by scientists, who gained high international prestige in cardiovascular science and clinical cardiology. The Journal is currently cited and indexed in major Abstracting & Indexing databases: Web of Science, Medline and Scopus. The Journal''s primary objectives Contribute to raising the professional level of medical researchers, physicians and academic teachers. Present the results of current research and clinical observations, explore the effectiveness of drug and non-drug treatments of heart disease, inform about new diagnostic techniques; discuss current trends and new advancements in clinical cardiology, contribute to continuing medical education, inform readers about results of Russian and international scientific forums; Further improve the general quality of reviewing and editing of manuscripts submitted for publication; Provide the widest possible dissemination of the published articles, among the global scientific community; Extend distribution and indexing of scientific publications in major Abstracting & Indexing databases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信